Study drug via brain catheter for newly diagnosed GBM
Part of Cancer clinical trials.
This Phase 1/2 trial tests two experimental treatments delivered through a thin catheter placed in the brain for people with newly diagnosed glioblastoma (GBM). The goal is to see whether the treatment can be given safely and whether it may shrink or control the tumor after standard chemotherapy and radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have newly diagnosed GBM (a grade 4 brain tumor) with specific lab findings (IDH wildtype and MGMT unmethylated) and a small, measurable leftover tumor area that is suitable for catheter placement.
- You finished standard treatment: radiation plus temozolomide (TMZ) and then 2 cycles of TMZ after radiation.
- You feel well enough for procedures (Karnofsky performance score above 70%) and can get brain MRI with and without contrast.
- Blood tests are strong enough for surgery and healing (hemoglobin, neutrophils, platelets, kidney and liver tests within required ranges; and blood clotting tests within required limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CT-179 for people with glioblastoma, an aggressive type of brain cancer. The drug targets a protein that helps cancer cells grow, and the goal is to see if it is safe and whether it can slow the tumor down.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This Phase 1 study tests a new brain-tumor treatment in people with recurrent (coming back) high-grade glioma (brain cancer). The study uses injected medicine along with an implanted tumor device and aims to find whether the treatment is safe and can shrink or control tumors.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
Hear when a new Newly Diagnosed MGMT Unmethylated Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.